Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Adoptive T Cell Therapy Methodology

Neoantigens' Role in Immunotherapy

Immunotherapy and Helminthic Therapy

Immunotherapy: The Future of Lung Cancer Treatment?

Suppression Immunotherapies

Immunotherapy: Past, Present and Future

Activation Immunotherapies

Adoptive T Cell Therapy Applications

Latest Immunotherapy News and Research

Review outlines virtual tumor concept and next-generation immunotherapy

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

12 Jun 2026

New combination therapy improves outcomes in high-risk leukemia

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment outcomes and survival in patients with acute myeloid leukaemia (AML) with FLT3 gene mutations.

11 Jun 2026

FDA accepts immunotherapy drug for review in colon cancer treatment

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

11 Jun 2026

New treatment platform delivers full-length mRNA for Duchenne muscular dystrophy

A new treatment platform developed by researchers at The University of Texas MD Anderson Cancer Center was able to deliver messenger RNA (mRNA) of the full-length DMD gene into preclinical models of Duchenne muscular dystrophy, successfully restoring the production of an important muscle protein, dystrophin, and dramatically improving muscle strength, endurance and function in vivo.

11 Jun 2026

Machine learning model filters out the biological noise in liquid biopsy samples

A machine learning model developed by researchers at the Johns Hopkins Kimmel Cancer Center filters out the biological noise in liquid biopsy samples, helping clinicians better match therapies to their patients' tumors.

9 Jun 2026

Advanced MRI scans predict chronic kidney disease in patients undergoing nephrectomy

An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for innovative imaging research that may help physicians identify patients at increased risk of chronic kidney disease (CKD) before they undergo surgery for kidney tumors.

9 Jun 2026

AI-designed molecular switch uses caffeine to control engineered cells

For many of us, a warm cup of coffee is how we start our day. For Texas A&M Health researchers, it may also offer a new way to control engineered cells in future medicines.

8 Jun 2026

Rice University receives CPRIT funding to advance cancer research

New funding from the Cancer Prevention and Research Institute of Texas (CPRIT) will help Rice University advance cancer research on several fronts, from strengthening a core genetic engineering facility that serves researchers across Texas to supporting new studies in cancer immunotherapy and ovarian cancer.

8 Jun 2026

Popular supplement creatine supercharges critical immune cells fighting cancer

Creatine, the organic acid that is popularly taken as a supplement by athletes and bodybuilders, supercharges a critical class of immune cells that activate and prepare the body's key cancer-fighters, according to new UCLA research.

5 Jun 2026

Review highlights TIGIT as a promising second-generation immunotherapy target

Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response rates.

5 Jun 2026

Antibody fragment offers safer alternative for Alzheimer disease treatment

In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (KisunlaTM, from Eli Lilly and Company), both based on immunotherapy (the use of molecules from the immune system to treat diseases).

5 Jun 2026

New manufacturing platform produces targeted mixtures of beneficial gut bacteria

Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for patients with recurrent Clostridioides difficile (C. difficile) infection.

3 Jun 2026

New atlas provides unprecedented overview of dendritic cell diversity across cancers

Researchers from VIB, VUB, and an international network of collaborators have created the most comprehensive single-cell atlas to date of tumor-associated dendritic cells.

1 Jun 2026

Targeting microRNA pathway helps overcome cancer immunotherapy resistance

Immune checkpoint therapy, a type of cancer immunotherapy that helps the immune system recognize and attack tumors, has transformed cancer treatment.

1 Jun 2026

Vaccine and drug combination cuts melanoma recurrence by half

The combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence by 49 percent, a new study shows.

1 Jun 2026

New PET imaging tracks tumor progression and cardiac inflammation during cancer therapy

A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses during cancer treatment.

1 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients

Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients with advanced stage or recurrent endometrial cancer when compared to chemotherapy alone.

29 May 2026

Teclistamab delivers deeper responses in relapsed myeloma patients

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

29 May 2026

AI-powered atlas maps immune structures across multiple cancer types

In a new study published today in Science, researchers from The University of Texas MD Anderson Cancer Center developed a spatial atlas of specialized immune structures, called tertiary lymphoid structures (TLSs), across multiple cancer types.

28 May 2026